About the journal
Molecular Cancer Therapeutics is a journal published by American Association for Cancer Research in United States. It is listed in MEDLINE and PUBMED according to the sources read. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- American Association for Cancer Research
- ISSN
- 1535-7163 · 1538-8514
- Country
- United States
- Access
- Not open access / not declared
- Official website
- http://mct.aacrjournals.org
Index listings
- MEDLINE · 2001-01-01
- PUBMED · 2022-03-01
- Indexing
- MEDLINE · PUBMED
- APC
- —
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 208 days received→accepted — computed from PubMed (n=100)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
12723
Last recorded publication year
2026
h-index
217
i10-index
5207
From OpenAlex open data (CC0).
Editorial & policy5
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSS
- Norwegian register (HK-dir)— 2027
- Level 2 — top tier (~20% of the field's channels)
- Open references deposited at Crossref
- 36%
- ORCID iDs in current deposits
- 39%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity3
- Alternate titles
- Mol Cancer TherMCT
- Source type
- journal
- NLM unique ID (PubMed)
- 101132535
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Cancer-related Molecular Pathways
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
Show all subjects (50)
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Cancer Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Protein Degradation and Inhibitors
- RNA modifications and cancer
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Cancer therapeutics and mechanisms
- Microtubule and mitosis dynamics
- Microtubule and mitosis dynamics
- Advanced Breast Cancer Therapies
- DNA Repair Mechanisms
- DNA Repair Mechanisms
- Advanced Breast Cancer Therapies
- Cancer Mechanisms and Therapy
- Cancer Mechanisms and Therapy
- Epigenetics and DNA Methylation
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Peptidase Inhibition and Analysis
- Cell death mechanisms and regulation
- Cell death mechanisms and regulation
- Histone Deacetylase Inhibitors Research
- Histone Deacetylase Inhibitors Research
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ